



Development and Challenges of Respiratory Disease Vaccines

Guest Editor:

Prof. Xiaoming Yang

National Engineering Technology
Research Center for Combined
Vaccines, Wuhan, China

Deadline for manuscript
submissions:

closed (31 January 2024)

Message from the Guest Editor

The respiratory system is susceptible to pathogens. Currently, vaccines are available for respiratory diseases such as influenza, COVID-19, pneumonia, pertussis, and tuberculosis (TB). Some infectious respiratory diseases do not yet have a vaccine, such as respiratory syncytial virus (RSV) and the common cold. There are still many troubling issues with existing respiratory vaccines, such as the mutants of influenza virus and SARS-CoV-2; therefore, the development of universal vaccines is now a common concern. As for the RSV vaccine, vaccine-induced pathology is a big safety hurdle.

To achieve a more extensive understanding of recent scientific knowledge and current trends in the development of vaccines that protect against respiratory disease, this Special Issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute research works which highlight (i) correlates of protection, (ii) the action mechanism of novel vaccine candidates, (iii) vaccine protection and vaccine pathology, and (iv) the development of novel attenuated or universal respiratory disease vaccines.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)